Navigation Links
Alexion Reports First Quarter 2008 Results
Date:4/30/2008


Growing Awareness of PNH Drives Strong Demand for Soliris(R) in U.S. and

Europe

First Non-GAAP Profit; Sales Guidance Revised Upward

Pipeline Progress in Neurology and Cancer

First Quarter 2008 Financial Highlights:

- Soliris(R) (eculizumab) net product sales were $45.5 million in Q1 2008,

compared to net product sales of $33.9 million in Q4 2007.

- Q1 GAAP net loss was $4.2 million, or $0.11 net loss per share, compared

to a GAAP net loss of $12.3 million, or $0.33 net loss per share, in

Q4 2007.

- Q1 non-GAAP net income was $1.6 million, or $0.04 net income per share,

compared to a non-GAAP net loss of $8.5 million, or $0.23 net loss per

share, in Q4 2007.

CHESHIRE, Conn., April 30 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the quarter ended March 31, 2008.

First Quarter 2008 Financial Results:

For the three months ended March 31, 2008, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported total revenues of $45.6 million compared to total revenues of $6.3 million for the same period in 2007. First quarter 2008 revenues were primarily from net product sales of Soliris(R) (eculizumab): $45.5 million, compared to $1.0 million in the first quarter of 2007 and $33.9 million in the fourth quarter of 2007. Soliris, approved by the U.S. Food and Drug Administration (FDA) in March 2007 and the European Commission (EC) in June 2007, is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disea
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Alexion to Present at Bear Stearns Healthcare Conference
2. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
3. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
4. Alexion Reports Fourth Quarter and Full Year 2007 Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Earlier this year, A.J. O’Connor Associates ... association that represents research-based life science organizations in New ... AJO’s Vice President of Business Development & Executive Coach, ... that attracted over 750 attendees. , In one ... old cancer survivor shared his moving story of how, ...
(Date:4/1/2015)... England , April 1, 2015 ... biotechnology company developing novel biological drugs to treat ... pleased to announce the appointment of Christina ... will be responsible for providing medical and regulatory ... the Company. Dr. Coughlin has extensive ...
(Date:3/31/2015)... 31, 2015  Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... Conway, Arkansas . The over 16,000 square foot ... March 26 th 2015 and brings the total ... "This facility represents another milestone in our ...
(Date:3/31/2015)... Eastern Kentucky University is ranked among ... criminal justice degree programs by Nonprofitcollegesonline.com. , “We ... and high quality educational opportunities,” Editor Liz Robertson ... are confident that students will find both at ... site’s first “Students before Profits” list, and EKU ...
Breaking Biology Technology:HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Conway, Arkansas 2EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2
... Israel, December 2 InSightec Ltd. announced,today that ... with the ExAblate(R) system has the potential to ... have spread to,the bones (bone metastases). The results ... 11 online issue of Annals of Surgical Oncology, ...
... NicOx S.A.,(NYSE Euronext Paris: COX) today announced ... the commercial manufacture and supply of naproxcinod ... is NicOx, lead,investigational product and the first ... of,anti-inflammatory agents, which recently achieved positive results ...
... BASKING RIDGE, N.J., Dec. 2 Regado Biosciences, Inc., ... newly created position of Senior Vice President of Business ... McDonald brings to Regado nearly 20 years of experience ... operations, portfolio management and marketing. She will report ...
Cached Biology Technology:New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 2New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 3New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 4NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer 2
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... SALT LAKE CITYLeukemia is the most common childhood cancer; ... zebrafish at Huntsman Cancer Institute (HCI) at the University ... in T-cell acute lymphocytic leukemia (T-ALL), according to an ... research journal Oncogene . When compared to samples ...
... to humans, the bacteria and tiny plants living in the ... is quite different than ours for one, they can,t ... red meat for a pick-me-up. So where does their ... " points to a source on the seafloor: minute particles ...
... a specific sugar residue on the cell surface, which is ... Faissner has now been able to use LewisX for the ... researchers report on their results in the Journal of ... Antibodies that recognise the LewisX sugar residue are used routinely ...
Cached Biology News:Zebrafish models identify high-risk genetic features in leukemia patients 2As good as gold 2
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... available as a one-cabinet model, ...
... Description: Beta-Agarase is useful in recovering ... agarose. Beta-Agarase digests the agarose into ... Properties: Heat Inactivation: 65C, 15 min ... 6.5 Purity: Tested for contaminating endonucleases, ...
... called a ?cap? is present on ... mRNAs and many viral RNAs. Substitution ... of the GTP present in an ... the synthesis of transcripts with a ...
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: